title: Renal denervation in treatment-resistant hypertension: a reappraisal.
abstract: The Symplicity HTN-1 and 2 studies proposed renal denervation (RDN) as an effective and safe approach to treat patients with resistant hypertension, and were followed by an unprecedented wave of enthusiasm. The announcement that Symplicity HTN-3 failed to meet its primary efficacy endpoint put an abrupt stop to these overoptimistic expectations. The use of a sound methodology was enough to see the typical 25-30mmHg systolic blood pressure decrease observed after RDN melt down to <3mmHg. RDN certainly deserves further investigation but is not ready for wide clinical application. For the time being, physicians should focus on improvement of drug adherence and skilful drug treatment adjustment, which allow reaching blood pressure target in the large majority of hypertensive patients.
authors.affiliation: Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. Electronic address: alexandre.persu@uclouvain.be.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Persu
authors.affiliation: Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
authors.forename: Yu
authors.initials: Y
authors.lastname: Jin
authors.affiliation: Department of General Internal Medicine, Ullevaal University Hospital, University of Oslo, Faculty of Medicine, Oslo, Norway; Department of Cardiology, Ullevaal University Hospital, University of Oslo, Faculty of Medicine, Oslo, Norway.
authors.forename: Fadl Elmula M
authors.initials: FE
authors.lastname: Fadl Elmula
authors.affiliation: Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
authors.forename: Jean
authors.initials: J
authors.lastname: Renkin
authors.affiliation: Department of Nephrology, Ullevaal University Hospital, University of Oslo, Faculty of Medicine, Oslo, Norway.
authors.forename: Aud
authors.initials: A
authors.lastname: Høieggen
authors.affiliation: Department of Cardiology, Ullevaal University Hospital, University of Oslo, Faculty of Medicine, Oslo, Norway.
authors.forename: Sverre E
authors.initials: SE
authors.lastname: Kjeldsen
authors.affiliation: Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; VitaK Research and Development, Maastricht University, Maastricht, The Netherlands.
authors.forename: Jan A
authors.initials: JA
authors.lastname: Staessen
mesh_terms: D004351:Drug Resistance; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery*; D007668:Kidney / Q000294:innervation / Q000601:surgery*; D013562:Sympathectomy